Table 3.
Subgroup Analysis of Associations of Nonadherence with Patient-Reported Outcomes of Psoriasis by Main Treatment
| Patient-Reported Outcomes | Nonadherence to Biological Treatment | Nonadherence to Systemic Treatment | Nonadherence to Topical Treatment | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <2 Weeks | ≥2 Weeks | <2 Weeks | ≥2 Weeks | <2 Weeks | ≥2 Weeks | |||||||
| AORa (95% CI) | P | AORa (95% CI) | P | AORa (95% CI) | P | AORa (95% CI) | P | AORa (95% CI) | P | AORa (95% CI) | P | |
| Deteriorated psoriasis | 3.22 (0.89, 11.63) | 0.074 | 11.50 (2.30, 57.55) | 0.003 | 3.03 (0.89, 10.30) | 0.075 | 19.43 (3.99, 94.56) | <0.001 | 2.34 (1.30, 4.23) | 0.005 | 5.19 (2.77, 9.73) | <0.001 |
| Perceived stress (VAS ≥7) | 3.26 (0.69, 15.43) | 0.136 | 10.31 (1.49, 71.27) | 0.018 | 2.26 (0.35, 14.57) | 0.393 | 1.80 (0.29, 11.25) | 0.531 | 1.34 (0.59, 3.06) | 0.481 | 1.06 (0.43, 2.61) | 0.900 |
| Anxiety (GAD-2 ≥3) | 2.31 (0.51, 10.37) | 0.275 | 1.04 (0.22, 4.92) | 0.957 | 1.02 (0.27, 3.91) | 0.974 | 3.61 (0.97, 13.041) | 0.055 | 1.39 (0.66, 2.91) | 0.387 | 1.09 (0.49, 2.43) | 0.842 |
| Depression (PHQ-2 ≥3) | 1.62 (0.38, 6.88) | 0.511 | 1.08 (0.23, 5.06) | 0.923 | 3.26 (0.58, 18.41) | 0.181 | 9.18 (1.72, 48.98) | 0.009 | 2.18 (1.06, 4.50) | 0.035 | 2.64 (1.25, 5.58) | 0.011 |
Notes: aCompared with adherence to biological, systemic and topical treatment respectively; adjusted for education, course of psoriasis and body surface area of skin lesion.
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; VAS, visual analogue scale; GAD-2, two-item Generalized Anxiety Disorder; PHQ-2, two-item Patient Health Questionnaire.